85
Participants
Start Date
May 7, 2015
Primary Completion Date
June 3, 2024
Study Completion Date
June 3, 2024
ACY-241
Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
Pomalidomide
4 mg qd dosed on days 1-21 of a 28 day cycle
Dexamethasone
40 mg qd on days 1, 8, 15, 22
Local Institution - 101, New York
Local Institution - 103, Atlanta
Local Institution - 301, Pamplona
Local Institution - 108, Tampa
Local Institution - 300, Salamanca
Local Institution - 341, Nantes
Gabrail Cancer Center Research, Canton
Local Institution - 340, Lille
Local Institution - 330, Heidelberg
CTRC at The UT Health Science Center at San Antonio, San Antonio
Colorado Blood Cancer Institute, Denver
Local Institution - 109, Tucson
Local Institution - 111, Seattle
University of Miami Medical Center, Miami
Local Institution - 104, Boston
Local Institution - 105, Boston
Local Institution - 320, Athens
Lead Sponsor
Celgene
INDUSTRY